From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
ALDH1A3-IN-3 (compound 16) is a potent inhibitor of ALDH1A3, with an IC50 of 0.26 μM. ALDH1A3-IN-3 is also a good ALDH3A1 substrate. ALDH1A3-IN-3 can be used for the research of prostate cancer [1].
ALDH1A3-IN-1 (Compound 14) is a potent ALDH1A3 inhibitor, with an IC50 of 0.63 µM and a Ki of 0.46 µM. ALDH1A3-IN-1 can be studied in prostate cancer[1].
ALDH1A inhibitor 673A is an ALDH1A inhibitor. ALDH1A inhibitor 673A inhibits all three ALDH1A family members (IC50: 246 nM, 230 nM, 348 nM for ALDH1A1, ALDH1A2, ALDH1A3 respectively. ALDH1A inhibitor 673A induces necroptotic cell death preferentially in CD133+ ovarian CSCs. ALDH1A inhibitor 673A also inhibits chemotherapy-resistant tumor growth [1].
ALDH1A1-IN-5 (compound 25) is a potent aldehyde dehydrogenase 1A1(ALDH1A1) inhibitor with EC50 value of 83, 45, 43 µM for ALDH1A1, ALDH1A2, ALDH1A3, respectively. ALDH1A1-IN-5 has the potential for the research of high-grade serous ovarian cancer (HGSOC) [1].
ALDH1A1-IN-3 (compound 57) is an excellent and selective aldehyde dehydrogenase 1A1(ALDH1A1) inhibitor with an IC50 value of 0.379 μM. ALDH1A1-IN-3 can effectively improve glucose consumption in HepG2 cells. ALDH1A1-IN-3 can be used for researching glucose metabolism improvement [1].
ALDH1A3-IN-2 (Compound 15) is a potent inhibitor of ALDH1A3 with an IC50 of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH1A3-IN-2 has the potential for the research of cancer diseases [1].
ALDH1A1-IN-4 (compound A1) is a potent inhibitor of aldehyde dehydrogenase (ALDH) A1, with IC50 value of 0.32 μM. ALDH1A1-IN-4 plays an important role in cancer research [1].
ALDH1A1-IN-2 is a potent inhibitor of aldehyde dehydrogenase 1a1(aldh1a1). Aldehyde dehydrogenases (ALDH) constitute a family of enzymes that play a critical role in oxidizing various cytotoxic xenogenic and biogenic aldehydes. ALDH1A1-IN-2 has the potential for the research of cancer, inflammation, or obesity (extracted from patent WO2019089626A1, compound 295) [1].
ALDH1A1 Human Pre-designed siRNA Set A contains three designed siRNAs for ALDH1A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Aldh1a1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Aldh1a1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
ALDH1A1 Rat Pre-designed siRNA Set A contains three designed siRNAs for ALDH1A1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
ALDH1A2 Human Pre-designed siRNA Set A contains three designed siRNAs for ALDH1A2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
ALDH1A3 Human Pre-designed siRNA Set A contains three designed siRNAs for ALDH1A3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
ALDH1L1 Human Pre-designed siRNA Set A contains three designed siRNAs for ALDH1L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
ALDH1L2 Human Pre-designed siRNA Set A contains three designed siRNAs for ALDH1L2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
ALDH1B1 Human Pre-designed siRNA Set A contains three designed siRNAs for ALDH1B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
4-Diethylaminobenzaldehyde is a reversible aldehyde dehydrogenases (ALDHs) inhibitor, with a Ki of 4 nM for ALDH1. 4-Diethylaminobenzaldehyde displays potent anti-androgenic effect (IC50= 1.71μM) [1] .
CVT-10216 is a highly selective, reversible aldehyde dehydrogenase-2 (ALDH-2) inhibitor with an IC50 of 29 nM. CVT-10216 also has inhibitory effect of ALDH-1 with an IC50 of 1.3 μM. CVT-10216 can reduce excessive alcohol drinking in alcohol-preferring rats and exhibit anxiolytic effects [1].
IGUANA-1 free base (STL5-T-0057) is an selective ALDH1B1 inhibitor with an IC50 value of 30 nM. IGUANA-1 free base inhibits cell growth of SW480 cells in adherent and spheroid conditions with IC50 values of 2.46 and 0.39 μM, respectively. IGUANA-1 free base can be used for the research of cancer [1].
Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram, a copper ion carrier, with Cu 2+ increases intracellular ROS levels and induces cuproptosis [1] .
CM10 is a potent and selective aldehyde dehydrogenase 1A (ALDH1A) family inhibitor, with IC50s of 1700, 740, and 640 nM for ALDH1A1, ALDH1A2, and ALDH1A3, respectively. CM10 does not inhibit any of the other ALDH family members. CM10 can regulate metabolism and has anti-cancer activity [1].
IGUANA-1 is a potent inhibitor of ALDH1B1, which is a mitochondrial enzyme that promotes colorectal and pancreatic cancer. IGUANA-1 has significant inhibition against cancer cells [1].
NCT-505 is a potent and selective aldehyde dehydrogenase (ALDH1A1) inhibitor, with an IC50 of 7 nM, and weakly inhibits hALDH1A2, hALDH1A3, hALDH2, hALDH3A1 (IC50s, >57, 22.8, 20.1, >57 μM).
Win 18446 is an orally active testes-specific enzyme ALDH1a2 inhibitor, with an IC50 of 0.3 μM. Win 18446 reversibly inhibits spermatogenesis in many species and inhibits Retinoic acid (HY-14649) biosynthesis from Retinol (HY-B1342) within the testes [1] .
Trans-3-Indoleacrylic acid is a tryptophan metabolite, which promotes tumor development through inhibition of RSL3 (HY-100218A) induced ferroptosis via AHR-ALDH1A3-FSP1-CoQ10 axis, and facilitates colorectal carcinogenesis [1]
NCT-501 is a potent and selective theophylline-based inhibitor of aldehyde dehydrogenase 1A1(ALDH1A1), inhibits hALDH1A1 with IC50 of 40 nM, typically shows better selectivity over other ALDH isozymes and other dehydrogenases (hALDH1B1, hALDH3A1, and hALDH2, IC50 >57 μM).
NCT-501 hydrochloride is a potent and selective theophylline-based inhibitor of aldehyde dehydrogenase 1A1(ALDH1A1), inhibits hALDH1A1 with IC50 of 40 nM, typically shows better selectivity over other ALDH isozymes and other dehydrogenases (hALDH1B1, hALDH3A1, and hALDH2, IC50 >57 μM) [1] .
KS106 is a potent ALDH inhibitor with IC50s of 334, 2137, 360 nM for ALDH1A1, ALDH2, and ALDH3A1, respectively. KS106 shows antiproliferative and anticancer effects with low low toxic.KS106 significantly increases ROS activity, lipid peroxidation and toxic aldehyde accumulation. KS106 induces apoptosis and cell cycle arrest at the G2/M phase [1].
KS100 is a potent ALDH inhibitor with IC50s of 230, 1542, 193 nM for ALDH1A1, ALDH2, and ALDH3A1, respectively. KS100 shows antiproliferative and anticancer effects with low low toxic. KS100 significantly increases ROS activity, lipid peroxidation and toxic aldehyde accumulation. KS10600 induces apoptosis and cell cycle arrest at the G2/M phase [1].
α-NETA is a potent and noncompetitive choline acetyltransferase (ChA) inhibitor with an IC50 of 9 μM. α-NETA is a potent ALDH1A1 (IC50=0.04 µM) and chemokine-like receptor-1(CMKLR1) antagonist. α-NETA weakly inhibits cholinesterase (ChE; IC50=84 µM) and acetylcholinesterase (AChE; IC50=300 µM). α-NETA has anti-cancer activity [1] .
PROTAC NSD3 degrader-1 (compound 56) is a PROTAC targeting to Nuclear receptor binding SET domain protein NSD3. PROTAC NSD3 degrader-1 specifically induces NSD3 degradation with DC50 values of 1.43 and 0.94 μM in lung cancer cells NCI-H1703 and A549, respectively. PROTAC NSD3 degrader-1 suppresses the methylation of H3K36, induces apoptosis, and causes cell-cycle arrest. PROTAC NSD3 degrader-1 also downregulates the expression of NSD3-associated genes such as CDC25A, ALDH1A1, and IGFBP.
Trans-3-Indoleacrylic acid is a tryptophan metabolite, which promotes tumor development through inhibition of RSL3 (HY-100218A) induced ferroptosis via AHR-ALDH1A3-FSP1-CoQ10 axis, and facilitates colorectal carcinogenesis [1]
ALDH1A1 Protein, Human (His) is a human recombinant ALDH1A1 with an N-terminal Met and His tag produced in E. coli. ALDH1A1 Protein, Human (His) contains 501 amino acids (1-501 a.a.).
ALDH1A2 Protein, Human (His) is a human recombinant ALDH1A2 with a N-terminal His tag produced in E. coli. ALDH1A2 Protein, Human (His) expresses the target gene encoding Met1-Ser518.
ALDH1A3 Protein, Human (His) is a human recombinant ALDH1A3 with a His tag at the N-terminus. ALDH1A3 Protein, Human (His) is produced in E. coli and the target gene encoding Met1-Pro512 is expressed.
The ALDH1A2 protein catalyzes the NAD-dependent oxidation of aldehyde substrates, including all-trans -retinal and all-trans 13,14-dihydroretinal. ALDH1A2 Protein, Human (P.pastoris, His) is the recombinant human-derived ALDH1A2 protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of ALDH1A2 Protein, Human (P.pastoris, His) is 518 a.a., with molecular weight of 58.7 kDa.
ALDH1A1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 55 kDa, targeting to ALDH1A1. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human, Mouse.
